Cleavage of GSDME by caspase-3 determines lobaplatin-induced pyroptosis in colon cancer cells
Open Access
- 25 February 2019
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cell Death & Disease
- Vol. 10 (3), 1-20
- https://doi.org/10.1038/s41419-019-1441-4
Abstract
Pyroptosis, a form of programmed cell death (PCD), has garnered increasing attention as it relates to innate immunity and diseases. However, the involvement of pyroptosis in the mechanism by which lobaplatin acts against colorectal cancer (CRC) is unclear. Our study revealed that treatment with lobaplatin reduced the viability of HT-29 and HCT116 cells in a dose-dependent manner. Morphologically, HT-29 and HCT116 cells treated with lobaplatin exhibited microscopic features of cell swelling and large bubbles emerging from the plasma membrane, and transmission electron microscopy (TEM) revealed multiple pores in the membrane. GSDME, rather than GSDMD, was cleaved in lobaplatin-induced pyroptosis in HT-29 and HCT116 cells due to caspase-3 activation. Knocking out GSDME switched lobaplatin-induced cell death from pyroptosis to apoptosis but did not affect lobaplatin-mediated inhibition of growth and tumour formation of HT-29 and HCT116 cells in vivo and in vitro. Further investigation indicates that lobaplatin induced reactive oxygen species (ROS) elevation and JNK phosphorylation. NAC, a ROS scavenger, completely reversed the pyroptosis of lobaplatin-treated HT-29 and HCT116 and JNK phosphorylation. Activated JNK recruited Bax to mitochondria, and thereby stimulated cytochrome c release to cytosol, followed by caspase-3/-9 cleavage and pyroptosis induction. Therefore, in colon cancer cells, GSDME mediates lobaplatin-induced pyroptosis downstream of the ROS/JNK/Bax-mitochondrial apoptotic pathway and caspase-3/-9 activation. Our study indicated that GSDME-dependent pyroptosis is an unrecognized mechanism by which lobaplatin eradicates neoplastic cells, which may have important implications for the clinical application of anticancer therapeutics.Keywords
This publication has 61 references indexed in Scilit:
- Activation and regulation of the inflammasomesNature Reviews Immunology, 2013
- Shedding Light on Apoptosis at Subcellular MembranesCell, 2012
- Genetic heterogeneity and cancer drug resistanceThe Lancet Oncology, 2012
- NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystalsNature, 2010
- Necroptosis, necrosis and secondary necrosis converge on similar cellular disintegration featuresCell Death & Differentiation, 2009
- Methylation of the DFNA5 increases risk of lymph node metastasis in human breast cancerBiochemical and Biophysical Research Communications, 2008
- Aberrant promoter methylation and tumor suppressive activity of the DFNA5 gene in colorectal carcinomaOncogene, 2008
- Identification of DFNA5 as a target of epigenetic inactivation in gastric cancerCancer Science, 2006
- JNK signaling pathway is a key modulator in cell death mediated by reactive oxygen and nitrogen speciesFree Radical Biology & Medicine, 2005
- Another way to die: autophagic programmed cell deathCell Death & Differentiation, 2005